Cover Image
市場調查報告書

低氧症 - 開發中產品分析

Hypoxia - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 321931
出版日期 內容資訊 英文 34 Pages
訂單完成後即時交付
價格
Back to Top
低氧症 - 開發中產品分析 Hypoxia - Pipeline Review, H2 2014
出版日期: 2014年12月31日 內容資訊: 英文 34 Pages
簡介

低氧症是指一般血中含氧濃度不足致使組織無法得到充分氧分的狀態,症狀有咳嗽、意識不清、呼吸緊迫、發汗、喘鳴、呼吸急促等。發病要素有慢性阻塞性肺病(COPD)和肺氣腫等肺部疾病,支氣管炎,肺水腫,心臟疾病,貧血等。

本報告提供低氧症治療藥的開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

低氧症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/實驗室

開發中產品的概要

  • 臨床階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/實驗室

治療藥的開發企業

  • Baxter International Inc

治療藥的評估

  • 單獨療法的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • Aes-103
  • F-15845
  • Recombinant Protein to Activate Protein S100-A8 and S100-A9 for Immunology and Respiratory
  • Recombinant Proteins for Ischemia Reperfusion Injury and Hypoxia
  • Small Molecule to Antagonize Notch Receptor for Pulmonary Arterial Hypertension and Hypoxia

最新的開發平台資訊

開發暫停中的計劃

附錄

圖表

目錄
Product Code: GMDHC5968IDB

Summary

Global Markets Direct's, 'Hypoxia - Pipeline Review, H2 2014', provides an overview of the Hypoxia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hypoxia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypoxia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hypoxia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hypoxia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hypoxia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hypoxia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hypoxia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hypoxia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hypoxia Overview
  • Therapeutics Development
    • Pipeline Products for Hypoxia - Overview
    • Pipeline Products for Hypoxia - Comparative Analysis
  • Hypoxia - Therapeutics under Development by Companies
  • Hypoxia - Therapeutics under Investigation by Universities/Institutes
  • Hypoxia - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Hypoxia - Products under Development by Companies
  • Hypoxia - Products under Investigation by Universities/Institutes
  • Hypoxia - Companies Involved in Therapeutics Development
    • Baxter International Inc.
  • Hypoxia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Aes-103 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • F-15845 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Activate Protein S100-A8 and S100-A9 for Immunology and Respiratory - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Proteins for Ischemia Reperfusion Injury and Hypoxia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize Notch Receptor for Pulmonary Arterial Hypertension and Hypoxia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hypoxia - Recent Pipeline Updates
  • Hypoxia - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hypoxia, H2 2014
  • Number of Products under Development for Hypoxia - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Hypoxia - Pipeline by Baxter International Inc., H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Hypoxia Therapeutics - Recent Pipeline Updates, H2 2014
  • Hypoxia - Dormant Projects, H2 2014

List of Figures

  • Number of Products under Development for Hypoxia, H2 2014
  • Number of Products under Development for Hypoxia - Comparative Analysis, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Targets, H2 2014
  • Number of Products by Stage and Top 10 Targets, H2 2014
  • Number of Products by Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Top 10 Molecule Types, H2 2014
  • Number of Products by Stage and Top 10 Molecule Types, H2 2014
Back to Top